Confronting the new epidemic: Integrated care for opioid use disorders.

2017 ◽  
Vol 35 (2) ◽  
pp. 248-250
Author(s):  
Christine N. Runyan ◽  
Amber L. Hewitt ◽  
Stephen A. Martin ◽  
Daniel Mullin
Keyword(s):  
Integrated Care ◽  
Opioid Use ◽  
Opioid Use Disorders

Viral vector-mediated gene therapy for opioid use disorders

2021 ◽  
pp. 113710
Author(s):  
Tao Wang ◽  
Xun Zhu ◽  
Hyun Yi ◽  
Jun Gu ◽  
Shue Liu ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Viral Vector ◽  
Opioid Use ◽  
Opioid Use Disorders

scholarly journals Suicide Risk and Addiction: The Impact of Alcohol and Opioid Use Disorders

2021 ◽  
Author(s):  
Mina M. Rizk ◽  
Sarah Herzog ◽  
Sanjana Dugad ◽  
Barbara Stanley
Keyword(s):  
Suicide Risk ◽  
Opioid Use ◽  
Opioid Use Disorders ◽  
The Impact

scholarly journals Prevalence and treatment of opioid use disorders among primary care patients in six health systems

2020 ◽  
Vol 207 ◽  
pp. 107732 ◽  
Author(s):  
Gwen Lapham ◽  
Denise M. Boudreau ◽  
Eric A. Johnson ◽  
Jennifer F. Bobb ◽  
Abigail G. Matthews ◽  
...  
Keyword(s):  
Primary Care ◽  
Health Systems ◽  
Opioid Use ◽  
Primary Care Patients ◽  
Opioid Use Disorders

scholarly journals Advances in the treatment of opioid use disorders

F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 87 ◽  
Author(s):  
George E. Woody
Keyword(s):  
Treatment Options ◽  
Geographical Location ◽  
Psychosocial Problems ◽  
Psychosocial Treatment ◽  
Prescription Opioid ◽  
Opioid Use ◽  
Improved Outcomes ◽  
Opioid Use Disorders ◽  
The Many ◽  
Prescription Opioid Use

The development of medications for treating persons with opioid use disorders has expanded the number of evidence-based treatment options, particularly for persons with the most severe disorders. It has also improved outcomes compared to psychosocial treatment alone and expanded treatment availability by increasing the number of physicians involved in treatment and the settings where patients can be treated. The medications include methadone, buprenorphine, buprenorphine/naloxone, and extended-release injectable naltrexone. Studies have shown that they are most effective when used over an extended, but as-yet-unspecified, period of time and with counseling and other services, particularly for the many with psychosocial problems. Though controversial in some cultures, well-designed studies in Switzerland, the Netherlands, Germany, and Canada have demonstrated the efficacy of supervised heroin injecting for persons who responded poorly to other treatments, and this treatment option has been approved by Switzerland and a few other E.U. countries. The degree to which medication-assisted therapies are available is dependent on many variables, including national and local regulations, preferences of individual providers and their geographical location, treatment costs, and insurance policies. Greater availability of medication-assisted therapies has become a major focus in the U.S. and Canada, where there has been a marked increase in deaths associated with heroin and prescription opioid use. This paper provides a brief summary of these developments.

Office-Based Practice and Opioid-Use Disorders

2003 ◽  
Vol 349 (10) ◽  
pp. 928-930 ◽  
Author(s):  
H. Westley Clark
Keyword(s):  
Opioid Use ◽  
Opioid Use Disorders
Sign in / Sign up

Export Citation Format

Share Document